Autoantibodies as biomarkers for breast cancer diagnosis and prognosis

Breast cancer is the most common cancer in women worldwide and is a substantial public health problem. Screening for breast cancer mainly relies on mammography, which leads to false positives and missed diagnoses and is especially non-sensitive for patients with small tumors and dense breasts. The prognosis of breast cancer is mainly classified by tumor, node, and metastasis (TNM) staging, but this method does not consider the molecular characteristics of the tumor. As the product of the immune response to tumor-associated antigens, autoantibodies can be detected in peripheral blood and can be used as noninvasive, presymptomatic, and low-cost biomarkers. Therefore, autoantibodies can provide a possible supplementary method for breast cancer screening and prognosis classification. This article introduces the methods used to detect peripheral blood autoantibodies and the research progress in the screening and prognosis of breast cancer made in recent years to provide a potential direction for the examination and treatment of breast cancer.

Automated summary

Breast cancer is a common and significant public health issue for women worldwide. Mammography, the main screening method for breast cancer, has limitations in terms of accuracy, especially for patients with small tumors and dense breasts. Recent research has found that autoantibodies in peripheral blood can serve as noninvasive, presymptomatic, and low-cost biomarkers, providing a potential supplementary method for breast cancer screening and prognosis classification.